Blog

qordata thought leaders and subject matter experts share their insights and experiences

Zafar Ahmed
Written By
Zafar Ahmed
September 22, 2017
0 Comments

The approach towards data privacy in EU makes consideration towards consent revocation an imperative. If a physician revokes consent, individual versus aggregate spend figures need to be recalculated, and they will show the corresponding changes. Thus, historical consent rate figures may not be an accurate indicator of transparency in that specific market, or even attitude shifts towards transparency. Interest groups that don’t examine consent from this angle tend to make hasty judgments on transparency. The fourth estate is a repeat offender, often citing (or misrepresenting) published data as a way of drawing public attention to “Big Pharma’s Big Money.” Not only does this present a distorted view of pharmaceutical spend activity to the public, but it also discourages relatively open […]

Ned Mumtaz
Written By
Ned Mumtaz
September 21, 2017
0 Comments

Physician consent can be a contentious issue. Especially when data privacy interpretation comes into play. In a webinar we hosted, Brian Sharkey, VP of Porzio Life Sciences LLC raised a question about the validity of consent rates as an indicator of pharmaceutical transparency. So, is there a direct correlation between transparency in the pharmaceutical sector and physicians’ attitudes towards consent? Let data give the answers.               How Are You Calculating Physician Consent? As we demonstrated in a webinar last year, the answer to ‘what is physician consent rate?’ can differ substantially depending on how you proceed with the consent calculation process. Some medical drug/device companies will calculate consent based on TOV amount. Hypothetically speaking, […]

Zafar Ahmed
Written By
Zafar Ahmed
September 20, 2017
0 Comments

How stringent are pharmaceutical disclosure requirements in your country? Depends on who you’re asking. Team qordata invited Brian Sharkey Vice President, Porzio Life Sciences LLC, to host our webinar on “EFPIA Reporting and Consent Management”. What he had to say pretty much confirms that when it comes to compliance disclosure, context is key. Some Measures Go Up, Some Go Down Did anticipated publication match actual publication rates in pharmaceutical spend for 2015 data? Not quite. Switzerland, at 72% was the only country in the EFPIA region where estimated consent equated to actual consent rate. Only three countries, the UK, Italy and Norway experienced the receipt of consent rates which exceeded their estimates; though the difference was marginal (not more than […]

Mohammad Ovais
Written By
Mohammad Ovais
September 15, 2017
0 Comments

Yes, the journey of a thousand miles does begin with a single step.  For pharmaceutical compliance/transparency professionals, that journey would be a lot longer, and a lot less rewarding if they weren’t able to get analytics out of a demanding and intense compliance process. Once the reporting phase has been completed, it’s time for compliance professionals to examine the data and report exceptions to management. Analysis is the ‘reward’ part of their hard work. But is Phase II of the transparency/compliance process really as simple as that? Let’s imagine the case of a hypothetical transparency/compliance professional, XYZ, who works at ABC Pharma: XYZ has succeeded in setting the spend data machinery rolling. This means, that at pre-specified intervals in the […]

Upcoming Event

Life Sciences GDPR Bootcamp

14 Nov to 14 Nov, 2017
10:00 am To 6:00 pm BST
DETAILS

Ask an Expert

Get all the insights, and the answers to the most critical issues in pharma compliance from thought leaders in qorcommunity

Get Answer
OUR SOLUTIONS CAN SIMPLIFY YOUR COMPLIANCE EFFORTS.